Psyence Biomedical (Psyence Biomedical) Total Assets : $1.57 Mil (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Total Assets?

Psyence Biomedical's Total Assets for the quarter that ended in Mar. 2023 was $1.57 Mil.

During the past 12 months, Psyence Biomedical's average Total Assets Growth Rate was 225.30% per year.

Total Assets is connected with ROA %. Psyence Biomedical's annualized ROA % for the quarter that ended in Mar. 2023 was -183.31%. Total Assets is also linked to Revenue through Asset Turnover. Psyence Biomedical's Asset Turnover for the quarter that ended in Mar. 2023 was 0.00.

Psyence Biomedical Total Assets Historical Data

The historical data trend for Psyence Biomedical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Total Assets Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Total Assets

4.92

1.81

1.57

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Total Assets	4.92	1.81	1.57

Psyence Biomedical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Psyence Biomedical's Total Assets for the fiscal year that ended in Mar. 2023 is calculated as

Total Assets	=	Total Equity (A: Mar. 2023 )	+	Total Liabilities (A: Mar. 2023 )
	=	-0.198	+	1.771
	=	1.57

Psyence Biomedical's Total Assets for the quarter that ended in Mar. 2023 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2023 )	+	Total Liabilities (Q: Mar. 2023 )
	=	-0.198	+	1.771
	=	1.57

Psyence Biomedical (NAS:PBM) Total Assets Explanation

Total Assets is connected with ROA %.

Psyence Biomedical's annualized ROA % for the quarter that ended in Mar. 2023 is

ROA %	=	Net Income (Q: Mar. 2023 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Mar. 2023 ))	/ count )
	=	-3.097	/	( (1.806	+	1.573)	/ 2 )
	=	-3.097	/	1.6895
	=	-183.31 %

Note: The Net Income data used here is one times the annual (Mar. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Psyence Biomedical's Asset Turnover for the quarter that ended in Mar. 2023 is

	Asset Turnover
=	Revenue (Q: Mar. 2023 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Mar. 2023 ))	/ count )
=	0	/	( (1.806	+	1.573)	/ 2 )
=	0	/	1.6895
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Psyence Biomedical Total Assets Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024